Matriptase is commonly dysregulated in carcinomas through elevated expression, increased zymogen activation, and an imbalance in the expression of matriptase relative to hepatocyte growth factor activator inhibitor (HAI)-1, the primary endogenous protease inhibitor of matriptase activity [8]–[10]. This evidence concerns the gene SPINT1 and carcinoma.